Clinical Trial: SIRT With Tremelimumab and Durvalumab for Resectable HCC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Resectable Hepatocellular Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma
Brief Summary:
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.The names of the interventions involved in this study are:Durvalumab (a type of immunotherapy)Tremelimumab (a type of immunotherapy)Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Read more